Qiagen ( (QGEN) ) just unveiled an update.
Qiagen N.V. announced a managerial transaction involving Stephen Rusckowski, a member of its administrative or supervisory body. The transaction involved the grant of 5,990 Restricted Stock Units linked to the exercise of share option programs, dated February 28, 2025, and conducted outside a trading venue. This announcement highlights Qiagen’s ongoing internal financial activities and may influence stakeholders’ perceptions of the company’s governance and executive incentives.
More about Qiagen
Qiagen N.V. is a company operating in the biotechnology industry, primarily focusing on the development and commercialization of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on various stock exchanges including the Frankfurt Stock Exchange and the New York Stock Exchange.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.